Last reviewed · How we verify

NCT03964376: POSAII

Nasal High Flow Therapy in Surgical Patients with Unrecognized Obstructive Sleep Apnea

Completed NA Last updated 13 January 2025
What this trial tests

NA trial testing Nasal High Flow in Obstructive Sleep Apnea in 22 participants. Completed in 8 January 2025.

Timeline
1 October 2019
Primary endpoint
8 January 2025
8 January 2025

Quick facts

Lead sponsorUniversity Health Network, Toronto
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment22
Start date1 October 2019
Primary completion8 January 2025
Estimated completion8 January 2025
Sites8 locations across Hong Kong, Singapore, Canada, Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

University Health Network, Toronto

Who can join

45 and older, any sex, with Obstructive Sleep Apnea or Sleep Disordered Breathing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study the investigators will determine whether using high flow oxygen in moderate-to-severe Obstructive Sleep Apnea patients following a major non cardiac surgery is more efficacious than usual care in preventing decrease in oxygen level in blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Nasal High Flow

Trials testing the same drug.

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Other University Health Network, Toronto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03964376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing